<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02696408</url>
  </required_header>
  <id_info>
    <org_study_id>2015-07</org_study_id>
    <secondary_id>2015-A01492-47</secondary_id>
    <nct_id>NCT02696408</nct_id>
  </id_info>
  <brief_title>Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation</brief_title>
  <acronym>STOP MUCITES</acronym>
  <official_title>Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation : a Randomized Double Blind Multicenter Prospective Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de la Loire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Société Biophoton</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Cancérologie de la Loire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The LLLT has an anti-inflammatory, analgesic effect and accelerates the healing of ulcerated
      lesions. There are little data in the literature showing its efficacy in prevention of
      mucositis in cohorts of patients with hematopoietic stem cells transplantation.

      The main objective of this study is to assess the efficacy of a prophylactic low level laser
      therapy performed by nurses on the severity of oral mucositis during HSCT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main end point for efficacy is the reduction of severe mucositis (grade 3 or more). The
      secondary efficacy endpoints are the reduction of mucositis, whatever the grade, the
      reduction of time with mucositis, the time to onset of mucositis symptoms, the reduction of
      pain intensity and evaluation of quality of life.The secondary endpoints for safety are
      severe adverse events and potential toxicity. Patients will be allocated at inclusion with a
      1/1 ratio either to laser-on or laser-off groups. In the laser group, patients will undergo
      laser therapy performed by nurses, which will consist of irradiation of the whole oral cavity
      during 2 minutes with 250mW power. In the laser-off group, laser therapy will be carried out
      with equipment off during the same time, and still performed by nurses. Protective eye
      shields will be used to avoid detrimental effects on eyes and to keep the subjects blind.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2016</start_date>
  <completion_date type="Anticipated">July 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>prevalence of grade 3 mucositis and more</measure>
    <time_frame>30 days</time_frame>
    <description>prevalence of grade 3 and more mucositis following the classification proposed by WHO (world health organization)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of all grades of mucositis</measure>
    <time_frame>30 days</time_frame>
    <description>The number of all grades of mucositis will be reported at day 30 post graft for all patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of mucositis</measure>
    <time_frame>30 days</time_frame>
    <description>The duration of mucositis will be reported at day 30 post graft for all patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time of onset of mucositis</measure>
    <time_frame>30 days</time_frame>
    <description>time of onset of mucositis will be assessed by measuring the interval between the beginning of packaging and the first day of mucositis has been assessed at a grade 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>30 days</time_frame>
    <description>Pain will be reported for each patient during their participation: 30 days post graft maximum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>30 days</time_frame>
    <description>Quality of life will be reported for each patient during their participation: 30 days post graft maximum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>30 days</time_frame>
    <description>serious adverse events will be reported for each patient during their participation: 30 days post graft maximum.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">194</enrollment>
  <condition>Hematologic Malignancy</condition>
  <arm_group>
    <arm_group_label>Laser treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>preventive treatment performed by nurses of mucositis by laser treating daily by scanning the entire oral cavity for 2 minutes with a power of 250 mW associated with mouthwashes several times a day (standard preventive treatment of mucositis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>laser-off</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>daily laser-off session performed by nurses associated with mouthwashes several times a day (standard preventive treatment of mucositis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser treatment</intervention_name>
    <description>Patients randomized to the experimental arm receive in addition to mouthwash, preventive treatment of mucositis by LLLT performed by nurses consisting of daily scanning the entire oral cavity for 2 minutes with a power of 250 mW, starting with conditioning and ongoing until the onset of mucositis of grade 1.
If the mucositis is localised, preventive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), preventive laser is stopped for curative laser only.</description>
    <arm_group_label>Laser treatment</arm_group_label>
    <other_name>Oncolase DIGI D5W200</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients randomized to the Placebo arm receive in addition to mouthwash fictive laser treatment performed by nurses until the onset of mucositis of grade 1.
If the mucositis is localised, fictive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), fictive laser is stopped for curative laser only.</description>
    <arm_group_label>laser-off</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient undergoing autologous or allogeneic HSC (Hematopoietic Stem Cell)
             transplantation with myeloablative conditioning

          -  Patient affiliated to a social security

          -  Signed inform consent

        Exclusion Criteria:

          -  Patient undergoing HSCT (Hematopoietic Stem Cell Transplantation) with reduced
             intensity conditioning Slavin (FB2) or Seattle (F-2 Gy TBI)

          -  Protected major patient

          -  Pregnant woman

          -  Patient with pacemaker

          -  Epileptic Patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuelle TAVERNIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie Lucien Neuwirth</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmanuelle TAVERNIER, MD</last_name>
    <phone>04 77 91 70 60</phone>
    <phone_ext>+33</phone_ext>
    <email>emmanuelle.tavernier@icloire.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle JEANDET, Nurse</last_name>
    <phone>04 77 91 74 05</phone>
    <phone_ext>+33</phone_ext>
    <email>isabelle.jeandet@icloire.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuelle Nicolas-Virelizier, MD</last_name>
      <email>Emmanuelle.NICOLAS-VIRELIZIER@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuelle Nicolas-Virelizier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Souad Assaad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amine Belhabri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lila Gilis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure Lebras, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Sophie Michallet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Rey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Ducastelle, PhD</last_name>
      <email>sophie.ducastelle-lepretre@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles Salles, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Ducastelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fiorenza Barraco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène Labussière, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Etienne Paubelle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier Thomas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Wattel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mauricette Michallet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clément Rocher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Virginie Larcher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest en Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle Tavernier, PhD</last_name>
      <phone>04 77 91 70 60</phone>
      <phone_ext>+33</phone_ext>
      <email>emmanuelle.tavernier@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuelle Tavernier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérôme Cornillon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Guyotat, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fressia Honeyman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Lejeune, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2016</study_first_submitted>
  <study_first_submitted_qc>February 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2016</study_first_posted>
  <last_update_submitted>July 17, 2017</last_update_submitted>
  <last_update_submitted_qc>July 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mucositis</keyword>
  <keyword>Low level laser therapy</keyword>
  <keyword>Autograft</keyword>
  <keyword>Allograft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

